Targeting HIF-1α (hypoxia-inducible factor 1-alpha) offers a promising strategy for lung cancer treatment, as the HIF-1α pathway plays a key role in tumor adaptation to low oxygen, angiogenesis, metabolic changes, and survival, all contributing to cancer progression. The gene discussed is HIF1A; the disease is neoplasm.